| 0.455 -0.197 (-30.21%) | 02-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Safeguard Scientifics, Inc., while no longer actively pursuing new investments, previously functioned as a private equity and venture capital firm. It specialized in diverse funding approaches, including expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, and both growth-stage and early-stage investments. Initial investments typically targeted Series A through C funding rounds, with opportunistic engagement in seed-stage opportunities. The firm primarily directed its capital towards companies in the technology, financial services, and healthcare sectors. Within technology, its interests encompassed Software-as-a-Service (SaaS), adtech/digital media, the Internet of Everything (IoE), advanced security solutions, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, internet/new media, financial technology (fintech), cloud computing, mobile applications, social platforms, big data, in-memory computing, and select business services, often requiring up to $25 million in capital. In healthcare, Safeguard Scientifics backed ventures in molecular and point-of-care diagnostics, medical devices, regenerative medicine, broader medical technology, digital health, healthcare technology, specialty pharmaceuticals, and certain healthcare service providers. Geographically, the firm invested across the entire United States, with a particular focus on the Mid-Atlantic region, and also extended its reach to Southeastern Canada. Its typical investment sizes ranged from $5 million to $25 million for growth equity rounds, and between $5 million and $10 million for early-stage financing. Safeguard Scientifics commonly provided capital to a diverse array of entities, ranging from owner-financed or bootstrapped enterprises and corporate divisions to venture capital-backed companies seeking a strategic growth partner. Ideally, the firm aimed to be the largest shareholder in its portfolio companies, typically securing an ownership stake between 20% and 50%, although it occasionally took either a majority or a smaller position. A strong preference was given to companies leveraging proprietary technology and intellectual property. Furthermore, the firm generally pursued a board seat in its funded companies. Established in 1953 as Lancaster Corporation, the company officially adopted the name Safeguard Scientifics, Inc. in 1981. Its main office is situated in Radnor, Pennsylvania, complemented by an additional location in Weston, Massachusetts.
Thu, 23 Jul 2026
Safeguard Scientifics stock trades on fundamental restructuring and portfolio value - AD HOC NEWS
Tue, 21 Jul 2026
Safeguard Scientifics stock trades steadily as portfolio valuations and cash position shape the inve - AD HOC NEWS
Sun, 19 Jul 2026
SFE stock trades on valuation as Safeguard Scientifics focuses on portfolio exits - AD HOC NEWS
Thu, 08 Sep 2022
Rockwell Medical Appoints Heather Hunter SVP - citybiz
Wed, 02 Dec 2020
Safeguard Scientifics Stock Price Forecast. Should You Buy SFE? - StockInvest.us
Fri, 17 May 2019
Safeguard Scientifics' Partner Company Transactis Acquired by Mastercard - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|